

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 959 140 A2

3

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
24.11.1999 Bulletin 1999/47

(51) Int. Cl.⁶: C12Q 1/68, B01L 7/00

(21) Application number: 99106838.8

(22) Date of filing: 06.04.1999

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 18.05.1998 US 80589

(71) Applicant:
Becton, Dickinson and Company
Franklin Lakes, New Jersey 07417-1880 (US)

(72) Inventors:
• Haaland, Perry D.
Chapel Hill, North Carolina 27516 (US)

- Nadeau, James G.
Chapel Hill, North Carolina 27514 (US)
- Nycz, Colleen M.
Raleigh, North Carolina 27613 (US)
- Dean, Cheryl H.
Raleigh, North Carolina 27614 (US)
- Spargo, Catherine A.
Apex, North Carolina 27502 (US)

(74) Representative:
Jacobacci, Filippo
c/o JACOBACCI & PERANI S.p.A.
Corso Regio Parco, 27
10152 Torino (IT)

(54) Methods, apparatus and computer program products for determining quantities of nucleic acid sequences in samples using standard curves and amplification ratio estimates

(57) Methods for determining quantities of nucleic acid sequences in samples undergoing amplification utilize amplification ratio estimates (R^*) in operations to accurately perform absolute quantitation even when amplification factors for the target and control sequences undergoing amplification are different, time dependent or vary as a function of starting concentrations of nucleic acid sequences. These operations also take into account conversion efficiencies associated with the conversion of probes upon generation of target or control amplicons, but do not require the explicit calculation of such efficiencies. The operations also recognize that a preferred R^* should be determined based on a preferred statistical criterion to improve quantitation. In addition, the use of standard samples having known starting concentrations of target and control sequences therein may enable accurate absolute quantitation without the explicit calculation of amplification ratio estimates.

EP 0 959 140 A2

Description**Field of the Invention**

5 [0001] This invention relates to methods, apparatus and computer program products for characterizing nucleic acid sequences, and more particularly to methods, apparatus and computer program products for determining quantities of nucleic acid sequences in samples.

Background of the Invention

10 [0002] Quantitative nucleic sequence analysis plays an increasingly important role in the fields of biological and medical research. For example, quantitative gene analysis has been used to determine the genome quantity of a particular gene, as in the case of the human *HER-2* oncogene which is found at amplified levels in approximately 30% of human breast cancers. D.J. Slamon et al., *Science* 235, 177-182 (1987). More recently, gene and genome quantitation have
15 also been used in determining and monitoring the levels of human immunodeficiency virus (HIV) in patients throughout the different phases of HIV infection and disease. M.R. Furtado et al., *J. Virol.* 69, 2092-2100 (1995). It has been suggested that higher levels of circulating HIV and failure to effectively control virus replication after infection may be associated with a negative disease prognosis; in other words, there may be an association between virus level (HIV replication) and the pathogenesis of the disease. M. Paitak et al., *Science* 259, 1749-1754 (1993). Accordingly, an
20 accurate determination of HIV nucleic acid levels early in an infection may serve as a useful tool in diagnosing illness, while the ability to correctly monitor changing levels of viral nucleic acid throughout the course of an illness may provide clinicians with critical information regarding the effectiveness of treatment and progression of disease. Additionally, the determination of virion-associated HIV RNA levels in plasma represents a marker of viral replication with potential wide-spread applicability in assessment of the activity of antiretroviral therapy. *Id.*

25 [0003] Several methods have been described for the quantitative analysis of nucleic acid sequences. The polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR) have permitted the analysis of small starting quantities of nucleic acid (e.g., as little as one cell equivalent). See, e.g., S. Edmands et al. 1994, *PCR Methods Applic.* 3, 317-19; I.R. Rodriguez et al. 1992, *Nucleic Acids Res.* 20, 3528. Early reports of quantitative PCR report quantitation of the PCR product, but do not directly measure the initial target sequence quantity. F. Ferre 1992, *PCR Methods Applic.* 2, 1-9. In general, these methods involve measuring PCR product at the end of nonisothermal amplification and relating this endpoint measurement level back to the starting nucleic acid concentration. Unfortunately, the absolute amount of product generated does not always bear a consistent and easily quantifiable relationship to the amount of target sequence present at the initiation of the amplification reaction. The kinetics and efficiency of amplification of a target nucleic acid sequence may also be strongly dependent on the starting abundance of the target sequence and the sequence match
30 of the primers and target template. Thus, some RT-PCR amplification methods which rely on "endpoint" analysis may be capable of only revealing the presence or absence of the target nucleic acid sequence, but not the actual starting quantity with any degree of accuracy. For these reasons, comparison of the amount of specimen-derived PCR product to the amount of product from a separately amplified external control standard typically does not provide a highly accurate basis for quantitation.

40 [0004] One specific approach to nucleic acid amplification using PCR measures product quantity in the log phase of the reaction prior to the plateau. See, e.g., Kellogg et al. 1990, *Anal. Biochem.* 189, 202-208; S. Pang et al. 1990, *Nature* 343, 85-89. This method requires that each sample have equal input amounts of nucleic acid sequence and that each sample under analysis amplifies with identical efficiency up to the point of quantitative analysis. A gene sequence (contained in all samples at a relatively constant quantity) can be used for sample amplification efficiency normalization.
45 However, using conventional methods of PCR detection and quantitation, it may be extremely laborious to assure that all samples are analyzed during the log phase of the reaction, both for the target gene and the normalization gene.

[0005] Another method referred to as quantitative competitive PCR (QC-PCR) has also been developed and is now widely used for PCR quantitation. See, e.g., P.D. Siebert and J.W Larrick 1992, *Nature* 359, 557-558; and X. Tan et al. 1994, *Biochim. Biophys. Acta* 1215, 157-162. QC-PCR relies on the inclusion of a known amount of an internal control competitor in each reaction mixture. The efficiency of each reaction is also normalized to the internal competitor. To obtain relative quantitation, the unknown target PCR product is compared with the known competitor PCR product, usually via gel electrophoresis. The relative amount of target-specific and competitor DNA is measured and used to calculate the starting number of target templates. Basically, in this kind of analysis, the larger the ratio of target specific product to competitor specific product, the higher the starting DNA concentration.

55 [0006] However, articles by Luc Raeymaekers, entitled "A Commentary on the Practical Applications of Competitive PCR", *Genome Research* 5, pp. 91-94 (1995) and "Quantitative PCR: Theoretical Considerations with Practical Implications" *Analytical Biochemistry* 214, pp. 582-585 (1993) (hereinafter, the "Raeymaekers 1995" and "Raeymaekers 1993" articles), suggest that PCR, by itself, may not be an accurate quantitation assay, notwithstanding its extreme sen-

sitivity and specificity relative to other methods based on probe hybridization. In particular, because of the many amplification steps which take place during PCR, small differences in amplification efficiency may result in dramatic differences in product yield. Furthermore, because the exponential phase of the reaction is of limited duration (because of the accumulation of product), if PCR is run beyond the exponential phase into the saturation phase when endpoint analysis is performed, initial differences in the amount of template may become obscured. To compensate for some of these intrinsic difficulties associated with accurate quantitation using PCR, controls have been introduced. However, these controls may not adequately account for specific pitfalls associated with QC-PCR which uses an external standard sequence to facilitate quantitation.

[0007] As explained at page 92 of the Raeymaekers 1995 article, the prefix "QC" in QC-PCR refers to the fact that competition occurs between target and standard templates for available substrates when PCR is allowed to proceed into the saturation phase. Because the sum of the masses of both products cannot exceed some maximum value, the amount of product formed from one template will decrease with the increasing quantity of the other template. As will be understood by those skilled in the art, the products of target and standard sequences are discriminated either by a difference in length or by a specific restriction site in the region between the primer templates. In practice, a plurality of PCR tubes containing the same but unknown amount of target sequence is spiked with a dilution series of defined quantities of the standard. If the amplification factor is the same for both sequences, their ratio will remain constant during amplification and the amount of the unknown template can then be accurately quantitated from the ratio of the two products. Raeymaekers recommends that a "curve" be generated which relates the logarithm of the ratio of PCR products standard/target to the logarithm of the initial known amount of standard cDNA added (i.e., $\log(T_n/S_n)$ versus $\log(S_0)$). Here, Raeymaekers uses a plurality of samples and each sample has an aliquot portion of an unknown quantity of target and a respective known quantity of standard (S). The amount of initial target can then be read from the point on the curve where the amounts of target (T) and standard (S) are equal (i.e., where $S/T=1$ or $\log(S/T)=0$).

[0008] Raeymakers also explains that if there is a difference in the amplification factor, theory predicts a parallel shift of the curve. This shift will cause a displacement in the point of equivalence and a faulty quantification because the magnitude of the displacement typically cannot be detected (because a reference point is typically not available). According to Raeymaekers, any determination that the curve has a slope of -1 does not suggest that the amplification factors are the same for both target and standard. From these considerations, Raeymaekers concludes that if a PCR assay yields a curve relating $\log(T_n/S_n)$ to $\log(S_0)$ which is not linear or does not have a slope of -1 (or +1 in the event the abscissa provides $\log(T_0)$), it cannot be used for either absolute or relative quantitation. Moreover, the slope = -1 requirement for the curve is a necessary but not a sufficient condition for establishing that the amplification factors are the same for T and S and therefore not a sufficient condition for absolute quantitation. Instead, the requirement that the amplification factors are equal has to be independently demonstrated as a prerequisite to obtaining accurate absolute quantitation, without reliance on the curve, and such independent demonstration may be difficult to achieve particularly if the target and standard sequences are dissimilar. These conclusions are explained more fully at pages 584 and 92 of the Raeymaekers 1993 and 1995 articles, respectively.

[0009] Similar conclusions are also reached at page 632 of an article by G. Haberhausen et al., entitled "Comparative Study of Different Standardization Concepts in Quantitative competitive Reverse Transcription-PCR Assays" Journal of Clinical Microbiology, Vol. 36, No. 3, pp. 628-633 (1998). Finally, the attempts at quantitation which are illustrated by the curves of FIGS. 2, 4 and 6 of an article by M. Piatak et al., entitled "Quantitative Competitive Polymerase Chain Reaction for Accurate Quantitation of HIV DNA and RNA Species", BioTechniques, Vol. 14, No. 1, pp. 70-80 (1993), would appear to be flawed in view of Raeymaekers' conclusions and further because the absolute values of the slopes of these curves differ significantly from unity. The accuracy of the results of Piatak et al. which are predicted from "corrected" fluorescence indicia may also be limited because the indicia were not obtained in real-time during amplification, but only after termination of amplification.

[0010] Thus, notwithstanding these attempts to perform absolute quantitation using nonisothermal amplification techniques such as PCR, there continues to be a need for improved methods of accurately determining starting quantities of nucleic acid sequences undergoing amplification, which do not require the establishment of identical amplification factors as a prerequisite to performing absolute quantitation.

50 Summary of the Invention

[0011] It is therefore an object of the present invention to provide improved methods, apparatus and computer program products for determining starting quantities of nucleic acid target sequences in test samples undergoing nucleic acid amplification.

[0012] It is also an object of the present invention to provide methods, apparatus and computer program products for more accurately measuring absolute quantities of nucleic acid target sequences in test samples containing known starting quantities of nucleic acid control sequences therein, even if the amplification factors for the target and control sequences undergoing amplification are different and dependent on time and the starting concentrations of the target

and control sequences.

[0013] It is still another object of the present invention to provide improved methods, apparatus and computer program products for performing absolute quantitation of nucleic acids undergoing isothermal amplification using methods such as Strand Displacement Amplification (SDA).

[0014] These and other objects, features and advantages are provided, according to the present invention, by methods, apparatus and computer program products for performing absolute quantitation of starting quantities of nucleic acid target sequences in test samples containing respective known starting quantities of a nucleic acid control sequence therein. These operations to perform absolute quantitation may use amplification ratio estimates which take into account differences in amplification and related factors (e.g., detection efficiency) associated with competitive 10 amplification of nucleic acid control and target sequences using nucleic acid amplification methods which include isothermal amplification.

[0015] According to one preferred embodiment of the present invention, a plurality of standard samples and at least one test sample are formed. The plurality of standard samples each contain a known starting quantity of a nucleic acid control sequence and a known starting quantity of a nucleic acid target sequence therein. The starting concentrations 15 of the nucleic acid control sequence in the standard samples are also preferably set to equal levels to improve quantitation accuracy. The test sample contains a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence therein. The nucleic acid sequences in these standard samples and test sample are then amplified, preferably in parallel, during an amplification time interval. These sequences may be amplified using a preferred isothermal reaction method such as Strand Displacement Amplification 20 (SDA), however, a thermal cycling reaction method such as Polymerase Chain Reaction (PCR), may also be used. According to a preferred aspect of the present invention, the isothermal reaction method utilizes two differentially labeled detector probes (signal primers). One probe is specific for target sequences being amplified (i.e., target amplicons) and the other probe is specific for control sequences being amplified (i.e., control amplicons). During the amplification reaction, each detector probe binds to its specific amplicon and is then converted to a cleaved form which 25 preferably exhibits a much higher fluorescence intensity than the unconverted form of the probe.

[0016] Indicia of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and in the test sample are then measured in real-time, preferably at respective measurement time intervals (which may be normalized to respective measurement time points) in the amplification time interval if a real-time amplification method such as SDA is utilized. The indicia of the quantities of the nucleic acid control and target sequences being 30 amplified may take the form of fluorescence signals (e.g., fluorescence intensities or detectable fluorescent energy transfers) if the samples contain fluorescent indicators therein (e.g., fluorescent dyes, labels, intercalators, etc). For example, during each of a plurality of consecutive measurement time intervals within the amplification time interval, a plurality of fluorescence measurements may be performed on the plurality of control and test samples. However, other indicia which are suitable for real-time measurement (e.g., radioactive signals) may also be used instead of fluorescence. 35

[0017] The measured indicia may then be collected over a range of measurement time intervals as respective normalized target fluorescence and normalized control fluorescence curves (i.e., $NF_T(t)$ and $NF_C(t)$). For example, using mathematical techniques well known to those skilled in the art, fluorescence measurements for all measurement time intervals may be analyzed and then normalized to respective measurement time points within the amplification time 40 interval. Thus, if the normalized control fluorescence curves are generated as a two-dimensional graph, for example, the measurement time points may be assigned along the abscissa of the graph and the normalized fluorescence values may be assigned along the ordinate of the graph. Preferred operations are then performed to determine an amplification ratio (R^*) from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples. A magnitude of the starting quantity of the nucleic acid sequence in the test sample is then determined in a preferred manner from the amplification ratio and the measured indicia of the amplified quantities of the 45 nucleic acid control and target sequences in the test sample.

[0018] The operations to determine the amplification ratio assume that during amplification the number of nucleic acid control amplicons at time "t" (i.e., $C(t)$) and the number of nucleic acid target amplicons at time "t" (i.e., $T(t)$) can be determined with a good degree of accuracy from the following relationship: $\log(T(t)/C(t)r) = \log(T_0) - \log(C_0)$, where C_0 and T_0 represent the starting quantities of the nucleic acid control and target sequences in a respective control or 50 test sample, respectively, "r" represents the ratio of the target amplification factor to the control amplification factor (i.e., $r = (\exp^{\lambda_T}/\exp^{\lambda_C})$), and λ_T and λ_C represent the amplification rates for the target and control sequences.

[0019] Operations to determine the amplification ratio may also utilize the following preferred relationships: $T(t)\eta_T/N_P = (NF_T(t)-NF_{Tlbase})/\Delta_T$ and $C(t)\eta_C/N_P = (NF_C(t)-NF_{Clbase})/\Delta_C$, where N_P equals the starting number 55 of probes, η_T equals the number of probes converted for every target amplicon generated, η_C equals the number of probes converted for every control amplicon generated, Δ_T equals $(NF_{Tlmax}-NF_{Tlbase})$ and Δ_C equals $(NF_{Clmax}-NF_{Clbase})$, where NF_{Tlmax} represents a maximum fluorescence signal if all probes were converted. From these relationships, a comprehensive relationship for absolute quantitation can be determined as:

$\log [((NF_T(t) - NF_{T|base})\eta_C \Delta_C / ((NF_C(t) - NF_{C|base})\eta_T \Delta_T)] = \log (T_0) - \log (C_0)$, where the amplification ratio R^* represents $(\eta_T \Delta_T / \eta_C \Delta_C)$.

[0020] The operations to determine an amplification ratio R^* in a preferred manner do not require the separate determination of η_T , Δ_T , r , η_C and Δ_C . The operations also recognize that R^* may vary as a function of time "t", T_0 and C_0 , and that a preferred $R^*(t)$ should be determined based on a preferred statistical criterion. In particular, operations are performed to determine respective amplification ratios from indicia measurements performed during respective measurement time intervals within the amplification time interval, and then determine, relative to a statistical criterion, which of the amplification ratios better satisfies the statistical criterion against known starting quantities of the nucleic target sequences in the standard samples. These respective amplification ratios may also be determined as an average of 10 amplification ratios for a number of selected standard samples, with each ratio for each of the selected standard samples being determined at each of the measurement time points. For example, measurement indicia from two or more standard samples having identical starting quantities of control and target sequences (C_0, T_0) therein may be used to determine a respective average amplification ratio corresponding to measurement indicia obtained during a respective measurement time interval. In particular, the operations of the present invention preferably generate a set of amplification ratios $\{R_1^*, R_2^*, R_3^*, R_4^*, \dots, R_n^*\}$ with each ratio being an average value based on control samples having identical starting quantities of control and target sequences therein, for example, and also corresponding to an effective measurement time point along the abscissa of the graphs of $NF_T(t)$ and $NF_C(t)$.

[0021] According to another preferred embodiment of the present invention, operations for explicitly determining amplification ratio estimates may be bypassed by utilizing the measured indicia from the plurality of standard samples 20 to predict a best "time" to perform absolute quantitation. In particular, a statistical criterion, such as a conventional fit-to-line statistical criterion, may be applied to relationships between measured fluorescence indicia (at various time points within the amplification time interval) and the starting quantities of the nucleic acid target sequence in the standard samples, to determine a most preferred relationship upon which to base absolute quantitation. These relationships 25 preferably take the form of $\log [(NF_T(t) - NF_{T|base}) / (NF_C(t) - NF_{C|base})]$ versus $\log (T_0)$.

[0022] Still another preferred embodiment of the present invention includes an apparatus for determining a quantity 30 of a nucleic acid sequence in a test sample. This preferred apparatus comprises means, such as a fluorescence measurement tool, for measuring indicia of quantities of nucleic acid target and control sequences being amplified in a test sample, which contains an unknown starting quantity of the nucleic acid target sequence and a known starting quantity of the nucleic acid control sequence therein, and in a plurality of standard samples which each contain respective 35 known starting quantities of the nucleic acid control and target sequences therein. A computer program product is also provided for controlling operation of the measuring means and performing numerical calculations to carry out the above-described operations.

[0023] In particular, a preferred computer program product comprises a computer readable storage medium having 40 computer-readable program code means embodied in the medium. The preferred computer-readable program code means comprises computer-readable program code means for determining an amplification ratio from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples. Computer-readable program code means is also provided for determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the amplification ratio and the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the test sample. In addition, computer-readable program code means 45 is also provided for performing more detailed ones of the above-described operations numerically. This embodiment of the present invention therefore provides a tool which can more accurately perform absolute quantitation to determine starting quantities of nucleic acid target sequences in test samples, even if the amplification factors for the target and control sequences undergoing amplification are different and/or time dependent. These computer program products may be realized in whole or in part as software modules running on a computer system. Alternatively, a dedicated stand-alone system with application specific integrated circuits for performing the above described operations may be provided.

Brief Description of the Drawings

50 [0024]

FIG. 1 is a flow chart illustrating operations performed by methods, apparatus and computer program products according to a first embodiment the present invention.

FIG. 2 is a graph of normalized fluorescence curves $NF_C(t)$ and $NF_T(t)$ corresponding to a standard or test sample containing amplified quantities of control and target nucleic acid sequences therein.

FIG. 3 is a graph of $\log [(NF_T(t_{mi}) - 1) / (NF_C(t_{mi}) - 1) R_i^*]$ verus $\log (T_0)$ which facilitates determination of a magnitude of a starting quantity of a nucleic acid target sequence in a test sample.

FIG. 4 is a flow chart illustrating operations performed by methods, apparatus and computer program products

according to a second embodiment the present invention.

FIG. 5 is a graph of $\log [(\text{NF}_T(t_{\text{mi}})-1)/(\text{NF}_C(t_{\text{mi}})-1)]$ versus $\log (T_0)$ which facilitates determination of a magnitude of a starting quantity of a nucleic acid target sequence in a test sample.

FIG. 6 illustrates a general hardware description of apparatus for determining quantities of nucleic acid sequences in test samples, according to the present invention.

Description of Preferred Embodiments

[0025] The present invention will now be described more fully hereinafter with reference to the accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Like numbers refer to like elements throughout.

[0026] Referring now to FIG. 1, preferred operations 100 for performing absolute quantitation of starting quantities of nucleic acid target sequences (e.g., RNA, DNA) in test samples use amplification ratio estimates. These amplification ratio estimates take into account differences in amplification and related factors (e.g., detection efficiency) associated with competitive amplification of nucleic acid control and target sequences. According to a preferred embodiment of the present invention, a plurality of standard samples and at least one test sample are initially formed, Blocks 102 and 104. The plurality of standard samples each contain a known starting quantity of a nucleic acid control sequence and a known (and different) starting quantity of a nucleic acid target sequence therein and the test sample contains a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence therein. It is this unknown starting quantity of the nucleic acid target sequence that is to be determined by absolute quantitation. The starting concentrations of the nucleic acid control sequence in the standard samples are also preferably set to equal known levels to enable quantitation.

[0027] The nucleic acid sequences in these standard samples and test sample are then preferably amplified in parallel during an amplification time interval, Block 106. Alternatively, the amplification operations may be performed separately for each of the samples during respective nonoverlapping time intervals. These separate time intervals may then be normalized to a common starting time and time interval for purposes of analysis. As will be understood by those skilled in the art, the samples may be amplified according to any known nucleic acid amplification methods, including both thermal cycling amplification methods and isothermal amplification methods. The present invention can enhance absolute quantitation of nucleic acids amplified by either thermal cycling methods or isothermal methods, although the present invention may provide particular advantages to isothermal amplification methods.

[0028] Suitable thermal cycling methods useful in the practice of the present invention include, but are not limited to, the Polymerase Chain Reaction (PCR) (see, U.S Patent Nos. 4,683,202, 4,683,195 and 4,965,188); Reverse Transcriptase PCR (RT-PCR); DNA Ligase Chain Reaction (LCR) (see, International Patent Application No. WO 89/09835); and transcription-based amplification (see, e.g., D.Y. Kwok et al. 1989, *Proc. Natl. Acad. Sci. USA* 86, 1173-1177). Suitable isothermal amplification methods useful in the practice of the present invention include, but are not limited to, Strand Displacement Amplification (SDA) (see, e.g., Walker et al. 1992, *Proc. Natl. Acad. Sci. USA* 89, 392-396); Q- β replicase (Lizardi et al. 1988, *Bio/Technology* 6, 1197-1202); Nucleic Acid-Based Sequence Amplification (NASBA; R. Sooknanan and L. Malek 1995, *Bio/Technology* 13, 563-65); and Self-Sustained Sequence Replication (3SR; Guatelli et al. 1990, *Proc. Natl. Acad. Sci. USA* 87, 1874-1878). Exemplary SDA methods are also described in U.S. Patent Nos. 5,445,166 to Walker and 5,270,184 to Walker et al., the disclosures of which are hereby incorporated herein by reference.

[0029] The isothermal reaction method may utilize two differentially labeled detector probes (signal primers). One probe is specific for target sequences being amplified (i.e., target amplicons) and the other probe is specific for control sequences being amplified (i.e., control amplicons). During the amplification reaction, each detector probe binds to its specific amplicon and is then converted to a cleaved form which preferably exhibits a much higher fluorescence intensity than the unconverted form of the probe. These and other aspects associated with a preferred isothermal reaction method are more fully described in U.S. Patent No. 5,547,861 to Nadeau et al., entitled "Detection of Nucleic Acid Amplification"; U.S. Application Serial No. 08/865,675, to Nadeau et al., filed May 30, 1997, entitled "Detection of Nucleic Acid Sequences by Fluorescence Quenching" (Attorney Docket No. P-3746); and U.S. Application Serial No. 08/855,085, to Nadeau et al., filed May 13, 1997, entitled "Detection of Nucleic Acids by Fluorescence Quenching" (Attorney Docket No. P-3747); assigned to the present assignee, the disclosures of which are hereby incorporated herein by reference.

[0030] Indicia of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and in the test sample are then measured, preferably at respective measurement time intervals in the amplification time interval if a real-time amplification method such as SDA is utilized, Block 108. These measurements may be made by a microwell plate fluorescence measurement tool such as the CytoFluor Series 4000 from PerSeptive Biosystems.

The Model 7700 Sequence Detector, manufactured and distributed by Applied Biosystems, a division of Perkin Elmer, Foster City, California, may also be used as a measurement tool. The indicia of the quantities of the nucleic acid control and target sequences being amplified may take the form of fluorescence signals (e.g., fluorescence intensities or detectable fluorescent energy transfers) if the samples contain fluorescent indicators therein (e.g., fluorescent dyes, labels, intercalators, etc). Accordingly, the measurement tool may contain one or more photodetectors for measuring the fluorescence signals from the samples undergoing parallel amplification. The measurement tool may also contain a computer-controlled stepper motor so that the control and test samples can be arranged as an array of samples and automatically and repeatedly positioned opposite a photodetector upon measurement of fluorescence intensity. A preferred measurement tool is more fully described hereinbelow with reference to FIG. 6. Thus, during each of a plurality of consecutive measurement time intervals within the amplification time interval, a plurality of fluorescence measurements may be obtained from the plurality of control and test samples. Using techniques well known to those skilled in the art, the fluorescence measurements made during a respective measurement time interval may also be normalized to respective measurement time points.

[0031] Other indicia which are suitable for real-time measurement (e.g., radioactive signals) may also be used instead of fluorescence. For example, indicia of nucleic acid concentration may be provided by labels that produce signals detectable by fluorescence, radioactivity, colorimetry, X-ray diffraction or absorption, magnetism, or enzymatic activity. Chemiluminescence and fluorescence lifetime measurements may also be utilized. Suitable labels include, fluorophores, chromophores, radioactive isotopes (e.g., ^{32}P or ^{125}I), electron-dense reagents, enzymes, and ligands having specific binding partners (e.g., biotin-avidin). Labeling of nucleic acids may be achieved by a number of means, including chemical modification of a nucleic acid primer or probe. Suitable fluorescent labels may include non-covalently binding labels (e.g., intercalating dyes) such as ethidium bromide, propidium bromide, chromomycin, acridine orange, and the like. However, the use of covalently bound fluorescent agents is preferred in the present invention. Such covalently bound fluorescent labels include fluorescein and derivatives thereof such as FAM, HEX, TET and JOE (all of which can be obtained from the Applied Biosystems Division of Perkin Elmer, Foster City, California); rhodamine and derivatives such as Texas Red (Molecular Probes, Eugene, Oregon); ROX and TAMRA (Applied Biosystems, Foster City, CA); Lucifer Yellow; coumarin derivatives and the like. Another preferred indicia of nucleic acid concentration is fluorescence energy-transfer (FET), in which a fluorescent reporter (or "donor") label and a quencher (or "acceptor") label are used in tandem to produce a detectable signal that is proportional to the amount of amplified nucleic acid product (e.g., in the form of double-stranded nucleic acid) present in the reaction mixture. Yet another detection method is fluorescence polarization (FP) detection of nucleic acid amplification, as described in U.S. Patent No. 5,593,867 to Walker et al., assigned to the present assignee, the disclosure of which is hereby incorporated herein by reference. Fluorescence lifetime measurements may be made by a microwell fluorescence reader such as Flowstar, manufactured by BMG. Chemiluminescence measurements may be made by a luminometer such as the Luminoskan, manufactured by Labsystems. Radioactivity measurements may be made by a scintillation counter, such as the Beckman LS6500.

[0032] The measured indicia may then be collected over a plurality of consecutive measurement time intervals and processed to generate respective normalized target fluorescence and normalized control fluorescence curves (i.e., $\text{NF}_T(t)$ and $\text{NF}_C(t)$). For example, the fluorescence measurements for all measurement time intervals may be analyzed and then normalized to respective measurement time points and if the normalized control fluorescence curves are generated as a two-dimensional graph, the measurement time points may be assigned to the abscissa of the graph and the normalized fluorescence values may be assigned to the ordinate of the graph.

[0033] For example, FIG. 2 is a graph of normalized fluorescence curves $\text{NF}_C(t)$ and $\text{NF}_T(t)$ corresponding to a standard or test sample containing amplified quantities of control sequence (C_n) and target nucleic acid sequence (T_n) therein, where "n" represents the sample number. The normalized value of 1.0 on the y-axis of FIG. 2 represents $\text{NF}_{C\text{base}}$ and $\text{NF}_{T\text{base}}$, and Δ_T and Δ_C equal $(\text{NF}_T(t)|_{\max} - \text{NF}_{T\text{base}})$ and $(\text{NF}_C(t)_{\max} - \text{NF}_{C\text{base}})$, respectively. Additional details associated with the generation and analysis of normalized target fluorescence and normalized control fluorescence curves (i.e., $\text{NF}_T(t)$ and $\text{NF}_C(t)$, where "N" denotes "normalized") are provided in copending U.S. Application Serial No. 08/862,905, to Haaland, filed May 23, 1997, entitled "Methods, Apparatus and Computer Program Products for Determining Quantities of Nucleic Acid Sequences in Samples" (Attorney Docket No. P-3892), assigned to the present assignee, the disclosure of which is hereby incorporated herein by reference. As will be understood by those skilled in the art, the use of normalized data is preferred for facilitating higher accuracy quantitation, but is not absolutely necessary.

[0034] Referring again to FIG. 1, preferred operations are then performed to determine an amplification ratio (R') from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples, Block 110. A magnitude of the starting quantity of the nucleic acid sequence in the test sample is then determined in a preferred manner from the amplification ratio and the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the test sample, Block 112. The operations to determine the amplification ratio assume that during amplification, the number of nucleic acid control amplicons at time "t" (i.e., $C(t)$) and the number of nucleic acid target amplicons at time "t" (i.e., $T(t)$) can be determined with a good degree of accuracy from the following rela-

tionship:

$$\log (T(t)/C(t)r) = \log (T_0) - \log (C_0) \quad (1)$$

5 where C_0 and T_0 represent the starting quantities of the nucleic acid control and target sequences in a respective control or test sample, respectively, and "r" represents the ratio of the target amplification factor to the control amplification factor. As evident by equation (1), any variation in "r" will influence the y-intercept associated with a graph of $\log (T(t)/C(t)r)$ versus $\log (T_0)$. As will be understood by those skilled in the art, the ratio of the target amplification factor to the control amplification factor is typically expressed as:

$$10 \quad r = (\exp^{\lambda_T t} / \exp^{\lambda_C t}) \quad (2)$$

where λ_T and λ_C represent the amplification rates for the target and control sequences during amplification.

[0035] Operations to determine the amplification ratio also utilize the following preferred relationship which can be obtained from FIG. 2 and an understanding of the amplification method:

$$T(t)\eta_T/N_p = (NF_T(t) - NF_{T|base})/\Delta_T \quad (3)$$

$$C(t)\eta_C/N_p = (NF_C(t) - NF_{C|base})/\Delta_C \quad (4)$$

20 where N_p equals the starting number of probes, η_T equals the number of probes converted for every target amplicon generated, η_C equals the number of probes converted for every control amplicon generated. As described above with respect to FIG. 2, Δ_T equals $(NF_T(t)|_{max} - NF_{T|base})$ and Δ_C equals $(NF_C(t)|_{max} - NF_{C|base})$.

[0036] From these relationships, a comprehensive relationship for absolute quantitation can be determined as:

$$25 \quad \log [((NF_T(t)-NF_{T|base})\eta_C\Delta_C) / ((NF_C(t)-NF_{C|base})\eta_T\Delta_T r)] = \log (T_0) - \log (C_0) \quad (5)$$

where,

$$30 \quad R^* = \eta_T\Delta_T r / \eta_C\Delta_C \quad (6)$$

[0037] The operations described below to determine an amplification ratio R^* in a preferred manner do not require the separate and computationally expensive determination of η_T , Δ_T , r , η_C and Δ_C which may be functionally dependent on time and the starting concentrations T_0 and C_0 . Moreover, the amplification ratio R^* is not equivalent to the statistical fit-to-line correlation factor R and R^2 illustrated by FIGS. 2-6 of the aforementioned Piatak et al. article. The preferred operations also recognize that R^* may vary as a function of time "t" (and the starting concentrations T_0 and C_0) and that a preferred $R^*(t)$ should be determined based on a preferred statistical criterion (e.g., fit-to-line). Here, the reference to a "preferred" $R^*(t)$ may also be considered as a recognition that there exists a preferred point in time during amplification where $R^*(t, T_0, C_0)$ changes systematically to yield a curve of points which best approximates a straight line, as illustrated and described more fully hereinbelow with respect to FIG. 3.

[0038] In particular, operations are performed to determine respective amplification ratios from indicia measurements performed during respective measurement time intervals within the amplification time interval, and then determine, relative to a statistical criterion, which of the amplification ratios better satisfies the statistical criterion against known starting quantities of the nucleic target sequences in the standard samples. To improve quantitation, these respective amplification ratios R^* may also be determined as an average of amplification ratios determined for a number of selected standard samples, with each ratio for each of the selected standard samples being determined at each of the normalized measurement time points. These operations will now be described.

[0039] In particular, an amplification ratio $R^*(t_{mi})$ may be determined for a respective sample by combining equations (5) and (6) to yield:

$$50 \quad \log [(NF_T(t)-1)/(NF_C(t)-1)R^*] = \log (T_0) - \log (C_0) \quad (7)$$

where $NF_{C|base}$ and $NF_{T|base}$ have been set to the normalized value of 1.0 (see, e.g., y-axis of FIG. 2) and t_{mi} represents a respective normalized measurement time point on the x-axis of FIG. 2. By forming a first standard sample with equal starting quantities of nucleic acid control sequence and target sequence therein (i.e., $T_0 = C_0$), a first amplification ratio corresponding to the first starting sample can be determined from FIG. 2 as:

$$R^*(t_{mi}) = (NF_T(t_{mi})-1)/(NF_C(t_{mi})-1) \quad (8)$$

[0040] Operations are then performed which use the first estimated amplification ratio $R^*(t_{mi})$ to determine a plurality of log-log relationships (e.g., x-y graphs), with each log-log relationship corresponding to a respective time point in the plurality of time points t_{mi} . Each of these log-log relationships includes a respective data point for each of the standard samples (where T_0 is known). In particular, the log-log relationships may be determined as respective x-y graphs by plotting, for each respective t_{mi} , the left side of equation (7) versus $\log(T_0)$, using the corresponding first estimated amplification ratio $R^*(t_{mi})$.

[0041] As will be understood by those skilled in the art, each x-y graph will provide a curve of points with the number of points being equal to the number of standard samples. Conventional line-fitting algorithms can then be used to generate, for each graph, a line having a positive slope, for example. As explained more fully hereinbelow, a "best" line (corresponding to a "best" t_{mi}) can then be determined using a statistical criterion, and then the magnitude of the starting quantity of the nucleic acid target sequence in the test sample can be determined from the "best" line by calculating the left side of equation (7) for the test sample at the "best" t_{mi} , and then reading the corresponding value of $\log(T_0)$ off the line.

[0042] Referring now to FIG. 3, the "best" line may also be determined from a "best" average amplification ratio $R^*(t_{mi})$ by using an exemplary statistical criterion (fit-to-line) which will now be described. In particular, for each t_{mi} , a corresponding average amplification ratio R_i is determined using measurement indicia obtained from two (or more) standard samples (S_1 and S_2) which each have identical starting quantities of nucleic acid target and control sequences therein (i.e., $C_0=T_0$). As illustrated by the following relationships, a set of average amplification ratios can be generated as $\{R_1, R_2, R_3, \dots, R_i\}$:

$$R_1^* = (R(t_{m1})|_{S1} + R(t_{m1})|_{S2})/2 \quad (9.1)$$

$$R_2^* = (R(t_{m2})|_{S1} + R(t_{m2})|_{S2})/2 \quad (9.2)$$

$$R_3^* = (R(t_{m3})|_{S1} + R(t_{m3})|_{S2})/2 \quad (9.3)$$

* * * * *

$$R_i^* = (R(t_{mi})|_{S1} + R(t_{mi})|_{S2})/2 \quad (9.i)$$

[0043] Then, a respective x-y graph can be obtained for each t_{mi} , as illustrated by FIG. 3, with each data point corresponding to a respective standard sample (including points corresponding to S_1 , and S_2 which have the same x-value). A conventional line fitting algorithm can then be used to fit a corresponding line through the data points in each x-y graph. Then, because two of the standard samples have identical starting quantities of target and control sequences therein, the "calculated" magnitudes of the starting quantities of the nucleic acid target sequences in the two standard samples can be determined by using each line to read respective logarithms of these calculated magnitudes off each x-axis. These calculated magnitudes are illustrated as $T_0(C1)$ and $T_0(C2)$ on FIG. 3. Operations are then performed to determine which of the measurement time points t_{mi} yields "calculated" magnitudes which are closest to the known starting quantity of the nucleic acid target sequence in the two standard samples. For example, an average calculated magnitude can be determined by averaging the two calculated magnitudes $T_0(C1)$ and $T_0(C2)$ and then determining which average calculated magnitude is closest to the known starting quantity. The line which yields the closest average calculation is then used to determine the starting quantity of the nucleic acid target sequence in the test sample. This line corresponds to the "best" t_{mi} at which absolute quantitation should be performed to yield accurate results, notwithstanding the fact that the amplification factors associated with the target and control sequences are different.

[0044] According to another preferred embodiment of the present invention, operations for explicitly determining amplification ratio estimates may be bypassed by utilizing the measured indicia from the plurality of standard samples to directly predict a best "time" to perform absolute quantitation. In particular, a statistical criterion, such as a conventional fit-to-line statistical criterion, may be applied to relationships between measured fluorescence indicia (at various time points within the amplification time interval) and the starting quantities of the nucleic acid target sequence in the standard samples, to determine a most preferred relationship upon which to base absolute quantitation. These relationships preferably take the form of $\log[(NF_T(t) - NF_{Tbase})/(NF_C(t) - NF_{Cbase})]$ versus $\log(T_0)$, where NF_{Tbase} and NF_{Cbase} may be set to unity as illustrated by FIG. 2.

[0045] In particular, FIG. 4 illustrates preferred operations 200 for performing absolute quantitation of starting quantities of nucleic acid target sequences (e.g., RNA, DNA) in test samples by analyzing standard curves. These standard curves are determined from indicia measured in real-time during amplification from standard samples containing known starting quantities of control and target sequences therein (with the known starting quantities of the control sequence

preferably being the same in each of the standard samples). For example, according to this alternative embodiment, a plurality of standard samples and at least one test sample are initially formed, Blocks 202 and 204. The plurality of standard samples each contain a known starting quantity of a nucleic acid control sequence and a known starting quantity of a nucleic acid target sequence therein and the test sample contains a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence therein. The nucleic acid sequences in these standard samples and test sample are then preferably amplified in parallel during an amplification time interval, Block 206. Multiple sets of indicia (e.g., fluorescence indicia) of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and in the test sample are then measured in real-time, preferably at respective measurement time intervals within the amplification time interval if an amplification method such as SDA is preferably utilized, Block 208. Accordingly, during each of a plurality of consecutive measurement time intervals within the amplification time interval, a plurality of fluorescence measurements may be obtained from the plurality of control and test samples. The measured indicia may then be collected over a plurality of consecutive measurement time intervals and processed to generate respective normalized target fluorescence and normalized control fluorescence curves (i.e., $NF_T(t)$ and $NF_C(t)$) for each of the samples. For example, like the first embodiment, the fluorescence measurements for all measurement time intervals may be analyzed and then normalized to respective measurement time points and if the normalized control fluorescence curves are generated as a two-dimensional graph, the measurement time points may be assigned to the abscissa of the graph and the normalized fluorescence values may be assigned to the ordinate of the graph, as illustrated best by FIG. 2.

[0046] Referring still to FIG. 4, operations are then performed to determine respective relationships between the measured indicia and the known starting quantities of the target sequence in the standard samples, Block 210, at each of a plurality of measurement time points in the amplification time interval (e.g., t_{m1} , t_{m2} , ..., t_{mi}). These relationships may take the form of respective x-y graphs of $\log[(NF_T(t_{m1})-NF_{T|base})/(NF_C(t_{m1})-NF_{C|base})]$ versus $\log(T_0)$ for each of the plurality of standard samples. An exemplary x-y graph derived from fluorescence measurements made for each of the standard samples at a respective time point t_{mi} is illustrated by FIG. 5. Each graph contains a curve of discrete points with each point corresponding to a standard sample.

[0047] Operations are then performed at Block 212 to determine, relative to a statistical criterion, which of the first or second relationships better satisfies the statistical criterion against the known starting quantities of the target sequence in the plurality of standard samples. For example, with respect to first and second curves of discrete points of the type illustrated by FIG. 5, these operations may include operations to fit the first curve to a first line and fit the second curve to a second line and determine which of the first and second lines provides a better statistical fit to its respective curve. Here, the operations to determine which of the first and second lines provides a better statistical fit may include the operations of determining a first "T-value" as the slope of the first line divided by a standard error in the slope of the first line, determining a second "T-value" as the slope of the second line divided by a standard error in the slope of the second line and then selecting the curve which results in the largest T-value. The line corresponding to the selected curve is then used to determine a magnitude of the starting quantity of the nucleic acid target sequence in the test sample (T_{0test}), Block 214.

[0048] Another preferred embodiment of the present invention includes an apparatus 30 for determining quantities of nucleic acid target sequences in test samples, as illustrated by FIG. 6. This preferred apparatus comprises means 32, such as the aforementioned fluorescence measurement tool, for measuring indicia of quantities of nucleic acid target and control sequences being amplified in a test sample and being amplified in a plurality of standard samples. The apparatus 30 also operates under computer control. In particular, the measurement tool 32 is preferably operatively coupled to a general purpose or application specific computer controller 34. The controller 34 preferably comprises a computer program product(s) for controlling operation of the measurement tool 32 and performing numerical operations relating to the above-described steps. The controller 34 may accept set-up and other related data via a file 36, disk input 38 or data bus 40. A display 42 and printer 44 are also preferably provided to visually display the operations performed by the controller 34.

[0049] It will be understood by those having skill in the art that the functions performed by the controller 34 may be realized in whole or in part as software modules running on a general purpose computer system. Alternatively, a dedicated stand-alone system with application specific integrated circuits for performing the above described functions and operations may be provided. In particular, a preferred computer program product will comprise a computer readable storage medium having computer-readable program code means embodied in the medium. The preferred computer-readable program code means comprises computer-readable program code means for performing the operations described with respect to FIGS. 1 and 4 and throughout the present description.

[0050] In the drawings and specification, there have been disclosed typical preferred embodiments of the invention and, although specific terms are employed, they are used in a generic and descriptive sense only and not for purposes of limitation, the scope of the invention being set forth in the following claims. Moreover, the terminology in the present description and claims relating to graphs, plotting lines, determining linear relationships, determining "best" times, calculated magnitudes, etc. is intended to include the processing of data and variables internal to a processing unit (e.g.,

computer) containing memory and not limited to the physical acts of printing or plotting lines, curves, and graphs. The functions $F_T(t)$ and $(F_C(t))$ and the constants $F_{T|base}$ and $F_{C|base}$, as used in the claims, are also inclusive of respective functions and constants obtained using normalized data (i.e., $NF_T(t)$, $NF_C(t)$, $NF_{T|base}$ and $NF_{C|base}$).

5 **Claims**

1. A method of determining a quantity of a nucleic acid sequence in a sample, comprising the steps of

10 forming a plurality of standard samples which each contain a known starting quantity of a nucleic acid control sequence and a known starting quantity of a nucleic acid target sequence therein;

15 forming a test sample containing a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence;

20 amplifying quantities of the nucleic acid control and target sequences in each of the standard samples and the test sample, during an amplification time interval;

25 measuring indicia of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and the test sample;

determining an amplification ratio from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples; and

30 determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the amplification ratio and the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the test sample.

2. The method of Claim 1, wherein said step of determining an amplification ratio comprises the steps of:

25 determining control and target fluorescence relationships ($F_C(t)$) and ($F_T(t)$) as a function of time (t) for the first standard sample, from the measured control and target fluorescence intensities; and

determining an amplification ratio (R^*) based on the following relationship (where C_0 and T_0 represent the equal starting quantities of the nucleic acid control and target sequences in the first standard sample, respectively): $\log[(F_T(t)-F_{T|base})/((F_C(t)-F_{C|base})R^*)] = \log T_0 - \log C_0$.

30 3. The method of Claim 1, wherein said step of forming a plurality of standard samples comprises forming first and second standard samples which each contain equal starting quantities of nucleic acid control and target sequences therein; and wherein said measuring step comprises measuring first indicia of the amplified quantities of the nucleic acid control and target sequences in each of the standard samples and test sample during a first measurement time interval.

35 4. The method of Claim 3, wherein said step of determining a magnitude comprises the steps of:

40 determining control and target fluorescence relationships ($F_C(t)$) and ($F_T(t)$) as a function of time (t) for the third standard sample, from the measured control and target fluorescence intensities; and

determining a relationship between $(F_T(t)-F_{T|base})/((F_C(t)-F_{C|base})R_1^*)$ and T_0 , where T_0 represents the starting quantity of the nucleic acid target sequence in the third standard sample.

45 5. A method of determining a quantity of a nucleic acid sequence in a sample, comprising the steps of:

50 forming a plurality of standard samples which each contain a known starting quantity of a nucleic acid control sequence and a known starting quantity of a nucleic acid target sequence therein;

55 forming a test sample containing a known starting quantity of the nucleic acid control sequence and an unknown starting quantity of the nucleic acid target sequence;

amplifying quantities of the nucleic acid control and target sequences in the standard samples and test sample, during an amplification time interval;

measuring first and second indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples and test sample, during first and second measurement time intervals, respectively;

determining a first relationship between the first indicia and the known starting quantities of the nucleic acid target sequence in the standard samples;

determining a second relationship between the second indicia and the known starting quantities of the nucleic acid target sequence in the standard samples;

determining, relative to a statistical criterion, which of the first and second relationships better satisfies the sta-

tistical criterion against the known starting quantities of the nucleic acid target sequences in the standard samples; and
determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the first or second relationship determined to better satisfy the statistical criterion.

5 6. The method of Claim 5, wherein the plurality of standard samples have equal starting quantities of nucleic acid control sequence therein; wherein said step of determining a first relationship comprises determining a first set of points from $\log[(F_T(t_{m1})-F_{T1\text{base}})/(F_C(t_{m1})-F_{C1\text{base}})]$ versus $\log(T_0)$ for each of the plurality of standard samples, where T_0 represents the starting quantity of the nucleic acid target sequence in a respective standard sample and t_{m1} represents a first time point in the amplification time interval; and wherein said step of determining a second relationship comprises determining a second set of points from $\log[(F_T(t_{m2})-F_{T1\text{base}})/(F_C(t_{m2})-F_{C1\text{base}})]$ versus $\log(T_0)$ for each of the plurality of standard samples, where t_{m2} represents a second time point in the amplification time interval.

10 15 7. The method of Claim 6, wherein said step of determining which of the first and second relationships better satisfies the statistical criterion comprises the steps of:
filling the first set of points to a first line;
fitting the second set of points to a second line; and
20 determining which of the first and second lines provides a better statistical fit to its respective curve.

25 8. The method of Claim 7, wherein said step of determining which of the first and second lines provides a better statistical fit comprises the steps of:
determining a first T-value as the slope of the first line divided by a standard error in the slope of the first line; and
determining a second T-value as the slope of the second line divided by a standard error in the slope of the second line.

30 9. An apparatus for determining a quantity of a nucleic acid sequence in a sample, comprising:
means for measuring indicia of quantities of nucleic acid target and control sequences being amplified in a test sample, which contains an unknown starting quantity of the nucleic acid target sequence and a known starting quantity of the nucleic acid control sequence therein, and in a plurality of standard samples which each contain respective known starting quantities of the nucleic acid control and target sequences therein;
35 means for determining an amplification ratio from the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the standard samples; and
means for determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the amplification ratio and the measured indicia of the amplified quantities of the nucleic acid control and target sequences in the test sample.

40 10. An apparatus for determining a quantity of a nucleic acid sequence in a sample, comprising:
means for measuring first and second indicia of quantities of nucleic acid target and control sequences being amplified in a test sample and a plurality of standard samples, at first and second measurement time intervals, respectively, the test sample containing an unknown starting quantity of the nucleic acid target sequence and a known starting quantity of the nucleic acid control sequence therein and the plurality of standard samples each containing respective known starting quantities of the nucleic acid control and target sequences therein;
means for determining a first relationship between the first indicia and the known starting quantities of the nucleic acid target sequences in the standard samples;
45 means for determining a second relationship between the second indicia and the known starting quantities of the nucleic acid target sequences in the standard samples;
means for determining, relative to a statistical criterion, which of the first and second relationships better satisfies the statistical criterion against the known starting quantities of the nucleic acid target sequences in the standard samples; and
50 means for determining a magnitude of the starting quantity of the nucleic acid target sequence in the test sample from the first or second relationship determined to better satisfy the statistical criterion.

55




FIG. 1







FIG. 2



T_0

FIG. 3

**FIG. 4**







FIG. 6.



(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 959 140 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
10.12.2003 Bulletin 2003/50

(51) Int Cl.⁷: C12Q 1/68, B01L 7/00

(43) Date of publication A2:
24.11.1999 Bulletin 1999/47

(21) Application number: 99106838.8

(22) Date of filing: 06.04.1999

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 18.05.1998 US 80589

(71) Applicant: Becton Dickinson and Company
Franklin Lakes, New Jersey 07417-1880 (US)

(72) Inventors:

- Haaland, Perry D.
Chapel Hill, North Carolina 27516 (US)

- Nadeau, James G.
Chapel Hill, North Carolina 27514 (US)
- Nycz, Colleen M.
Raleigh, North Carolina 27613 (US)
- Dean, Cheryl H.
Raleigh, North Carolina 27614 (US)
- Spargo, Catherine A.
Apex, North Carolina 27502 (US)

(74) Representative: Rambelli, Paolo (IT)
Jacobacci & Partners S.p.A.
Corso Regio Parco 27
I-10152 Torino (IT)

(54) Methods, apparatus and computer program products for determining quantities of nucleic acid sequences in samples using standard curves and amplification ratio estimates

(57) Methods for determining quantities of nucleic acid sequences in samples undergoing amplification utilize amplification ratio estimates (R^*) in operations to accurately perform absolute quantitation even when amplification factors for the target and control sequences undergoing amplification are different, time dependent or vary as a function of starting concentrations of nucleic acid sequences. These operations also take into account conversion efficiencies associated with the conversion of probes upon generation of target or control amplicons, but do not require the explicit calculation of such efficiencies. The operations also recognize that a preferred R^* should be determined based on a preferred statistical criterion to improve quantitation. In addition, the use of standard samples having known starting concentrations of target and control sequences therein may enable accurate absolute quantitation without the explicit calculation of amplification ratio estimates.




FIG. 2



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 10 6838

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	ZHANG J ET AL: "A novel highly reproducible quantitative competitive RT PCR system" JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 274, no. 3, 5 December 1997 (1997-12-05), pages 338-352, XP004451568 ISSN: 0022-2836 * the whole document *	1	C12Q1/68 B01L7/00
Y	---	2-10	
X	GIBSON U E M ET AL: "A NOVEL METHOD FOR REAL TIME QUANTITATIVE RT-PCR" GENOME RESEARCH, COLD SPRING HARBOR LABORATORY PRESS, US, vol. 6, no. 10, 1 October 1996 (1996-10-01), pages 995-1001, XP000642796 ISSN: 1088-9051	1	
Y	* page 997, column 2, line 5 - page 999, column 1, last paragraph; figures 1-3 *	2-10	
X	---		TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Y	EP 0 640 828 A (HOFFMANN LA ROCHE) 1 March 1995 (1995-03-01)	1,9,10	C12Q
Y	* column 25, line 23 - column 26, line 23; claim 24; figure 11 *	2-8	
X	---		
X	EP 0 623 682 A (BECTON DICKINSON CO) 9 November 1994 (1994-11-09)	1	
Y	* claims 6-10 *	2-10	
X	---		
X	WO 97 41261 A (IMMUNOLOGICAL ASSOCIATES OF DE) 6 November 1997 (1997-11-06)	1	
Y	* page 8, line 12 - page 9, line 13; claim 16 *	2-10	
Y	---	-/-	
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
MUNICH		20 October 2003	Stachowiak, O
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons B : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 99 10 6838

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	BORTOLIN SUSAN ET AL: "Quantitative RT-PCR combined with time-resolved fluorometry for determination of BCR-ABL mRNA" CLINICAL CHEMISTRY, vol. 42, no. 12, 1996, pages 1924-1929, XP009018965 ISSN: 0009-9147 * the whole document * ---	1	
Y	HABERHAUSEN ET AL: "Comparative study of different standardization concepts in quantitative competitive reverse transcription PCR-assays" JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 36, no. 3, March 1998 (1998-03), pages 628-633, XP002132721 ISSN: 0095-1137 * the whole document *	2-10	
D,A	HABERHAUSEN ET AL: "Comparative study of different standardization concepts in quantitative competitive reverse transcription PCR-assays" JOURNAL OF CLINICAL MICROBIOLOGY, WASHINGTON, DC, US, vol. 36, no. 3, March 1998 (1998-03), pages 628-633, XP002132721 ISSN: 0095-1137 * the whole document *	1	
Y	RAEYMAEKERS L: "QUANTITATIVE PCR: THEORETICAL CONSIDERATIONS WITH PRACTICAL IMPLICATIONS" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 214, no. 2, 1 November 1993 (1993-11-01), pages 582-585, XP000413714 ISSN: 0003-2697 * the whole document *	2-10	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
D,A	RAEYMAEKERS L: "QUANTITATIVE PCR: THEORETICAL CONSIDERATIONS WITH PRACTICAL IMPLICATIONS" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 214, no. 2, 1 November 1993 (1993-11-01), pages 582-585, XP000413714 ISSN: 0003-2697 * the whole document *	1-10	
		-/-	
The present search report has been drawn up for all claims			
Place of search	Date of completion of the search	Examiner	
MUNICH	20 October 2003	Stachowiak, O	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone	T : theory or principle underlying the invention		
Y : particularly relevant if combined with another document of the same category	E : earlier patent document, but published on, or after the filing date		
A : technological background	D : document cited in the application		
O : non-written disclosure	L : document cited for other reasons		
P : intermediate document	& : member of the same patent family, corresponding document		



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 99 10 6838

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
D,A	PIATAK M: "QUANTITATIVE COMPETITIVE POLYMERASE CHAIN REACTION FOR ACCURATE QUANTITATION OF HIV DNA AND RNA SPECIES" BIOTECHNIQUES, EATON PUBLISHING, NATICK, US, vol. 14, no. 1, 1993, pages 70-81, XP000331780 ISSN: 0736-6205 * the whole document * --- 	1-10	
D,A	RAEYMAEKERS L: "A commentary on the practical applications of competitive PCR." GENOME RESEARCH. UNITED STATES AUG 1995, vol. 5, no. 1, August 1995 (1995-08), pages 91-94, XP009018225 ISSN: 1088-9051 * the whole document * --- 	1-10	
D,A	KELLOGG D E ET AL: "QUANTITATION OF HIV-1 PROVIRAL DNA RELATIVE TO CELLULAR DNA BY THE POLYMERASE CHAIN REACTION" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 189, 1990, pages 202-208, XP000386282 ISSN: 0003-2697 * the whole document * --- 	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
D,A	FERRE F: "Quantitative or semi-quantitative PCR: reality versus myth." PCR METHODS AND APPLICATIONS. UNITED STATES AUG 1992, vol. 2, no. 1, August 1992 (1992-08), pages 1-9, XP009018224 ISSN: 1054-9803 * the whole document * --- -/- 	1-10	
The present search report has been drawn up for all claims			
Place of search MUNICH		Date of completion of the search 20 October 2003	Examiner Stachowiak, O
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 99 10 6838

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	RAEYMAEKERS L: "Comments on quantitative PCR." EUROPEAN CYTOKINE NETWORK. FRANCE 1994 JAN-FEB, vol. 5, no. 1, January 1994 (1994-01), pages 57;discussion 59-60, XP009018441 ISSN: 1148-5493 * page 57 *	1-10	
P,X	US 5 863 736 A (HAALAND PERRY D) 26 January 1999 (1999-01-26) * abstract; claims 1-19 *	5-8	
	-----		TECHNICAL FIELDS SEARCHED (Int.Cl.6)
The present search report has been drawn up for all claims			
Place of search MUNICH	Date of completion of the search 20 October 2003	Examiner Stachowiak, O	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 10 6838

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-10-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 0640828	A	01-03-1995		AT 192851 T AU 681682 B2 AU 7141494 A BR 9403338 A CA 2129787 A1 CN 1107892 A ,B CZ 9402078 A3 DE 69424353 D1 DE 69424353 T2 DK 640828 T3 EP 0640828 A1 ES 2147565 T3 FI 943936 A HU 71622 A2 IL 110732 A JP 7163397 A NO 943166 A NZ 264310 A PL 304805 A1 SG 47865 A1 ZA 9406330 A	15-05-2000 04-09-1997 09-03-1995 11-04-1995 28-02-1995 06-09-1995 15-11-1995 15-06-2000 04-01-2001 25-09-2000 01-03-1995 16-09-2000 28-02-1995 29-01-1996 15-07-1998 27-06-1995 28-02-1995 25-03-1998 06-03-1995 17-04-1998 28-02-1995
EP 0623682	A	09-11-1994		US 5457027 A AU 675503 B2 AU 6058094 A CA 2121658 A1 DE 69420454 D1 DE 69420454 T2 EP 0623682 A1 ES 2136137 T3 JP 3127079 B2 JP 6343497 A SG 50707 A1 US 5470723 A US 5561044 A US 5736365 A US 5840487 A	10-10-1995 06-02-1997 10-11-1994 06-11-1994 14-10-1999 23-12-1999 09-11-1994 16-11-1999 22-01-2001 20-12-1994 20-07-1998 28-11-1995 01-10-1996 07-04-1998 24-11-1998
WO 9741261	A	06-11-1997		AU 3116997 A EP 0910666 A1 WO 9741261 A1 US 6258543 B1 US 6063568 A	19-11-1997 28-04-1999 06-11-1997 10-07-2001 16-05-2000
US 5863736	A	26-01-1999		AU 738398 B2 AU 6474998 A	20-09-2001 26-11-1998

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 10 6838

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-10-2003

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 5863736 A		CA	2236067 A1	23-11-1998
